97O PREDIX HER2 trial: Event-free survival and pathologic complete response in clinical subgroups and stromal TILs levels
Thomas Hatschek(Karolinska University Hospital), Jonas Bergh(Karolinska Institutet), Yvonne Brandberg(Karolinska Institutet), Zakaria Einbeigi(Sahlgrenska University Hospital), Tobias Lekberg(Karolinska University Hospital), Erika Isaksson-Friman(Saint Göran Hospital), Ana Bosch(Memorial Sloan Kettering Cancer Center), Lena Carlsson(University of Gothenburg), Theodoros Foukakis(Karolinska Institutet), Mats Hellström(Karolinska University Hospital), Henrik Lindman(Uppsala University), Hemming Johansson(Karolinska Institutet), Anne Andersson(Umeå University), John Hartman(Stockholm South General Hospital), Judith Bjöhle(Karolinska University Hospital), Ioannis Zerdes(Karolinska University Hospital), Hanna Fredholm(Karolinska University Hospital), Ann Charlotte Dreifaldt(Örebro University Hospital), Ellinor Elinder(Stockholm South General Hospital)
Cited by 5
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
|New England Journal of Medicine|2007|4.6k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k